0000950170-24-077518.txt : 20240625 0000950170-24-077518.hdr.sgml : 20240625 20240625200002 ACCESSION NUMBER: 0000950170-24-077518 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arif Bilal CENTRAL INDEX KEY: 0001959750 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 241070347 MAIL ADDRESS: STREET 1: 215 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 ownership.xml 4 X0508 4 2024-06-21 0000873303 Sarepta Therapeutics, Inc. SRPT 0001959750 Arif Bilal 215 FIRST STREET CAMBRIDGE MA 02129 false true false false Chief Tech Ops Officer true Common Stock 2024-06-21 4 M false 6250 A 31472.00 D Common Stock 2024-06-24 4 F false 2352 164.64 D 29120.00 D Common Stock 2024-06-24 4 S false 5580 162.31 D 23540.00 D Common Stock 2024-06-24 4 S false 1055 163.83 D 22485.00 D Common Stock 2024-06-24 4 S false 300 164.61 D 22185.00 D Common Stock 2024-06-24 4 S false 700 166.10 D 21485.00 D Common Stock 2024-06-24 4 S false 224 167.13 D 21261.00 D Common Stock 2024-06-25 4 S false 3898 163.23 D 17363.00 D Performance Stock Units 2024-06-21 4 A false 6250 0 A Common Stock 6250 6250 D Performance Stock Units 2024-06-21 4 M false 6250 0 D Common Stock 6250 0 D Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.25 to $163.21, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.35 to $164.18, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.38 to $164.91, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.69 to $166.44, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.91 to $167.36, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. /s/ Ryan Brown as Attorney-in-Fact for Bilal Arif 2024-06-25